NF-κB- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells byEscherichia coliNissle 1917: a Novel Effect of a Probiotic Bacterium
2004/09/22 by Jan Wehkamp, Jürgen Harder, Jürgen Harder +12 · 28 citations
Immunology and Microbiology · Agricultural and Biological Sciences · Biochemistry, Genetics and Molecular Biology · #Antimicrobial Peptides and Activities #Probiotics and Fermented Foods #Biochemical and Structural Characterization
paper · doi:10.1128/iai.72.10.5750-5758.2004
Abstract
Little is known about the defensive mechanisms induced in epithelial cells by pathogenic versus probiotic bacteria. The aim of our study was to compare probiotic bacterial strains such as Escherichia coli Nissle 1917 with nonprobiotic, pathogenic and nonpathogenic bacteria with respect to innate defense mechanisms in the intestinal mucosal cell. Here we report that E. coli strain Nissle 1917 and a variety of other probiotic bacteria, including lactobacilli--in contrast to more than 40 different E. coli strains tested--strongly induce the expression of the antimicrobial peptide human beta-defensin-2 (hBD-2) in Caco-2 intestinal epithelial cells in a time- and dose-dependent manner. Induction of hBD-2 through E. coli Nissle 1917 was further confirmed by activation of the hBD-2 promoter and detection of the hBD-2 peptide in the culture supernatants of E. coli Nissle 1917-treated Caco-2 cells. Luciferase gene reporter analyses and site-directed mutagenesis experiments demonstrated that functional binding sites for NF-kappaB and AP-1 in the hBD-2 promoter are required for induction of hBD-2 through E. coli Nissle 1917. Treatment with the NF-kappaB inhibitor Helenalin, as well as with SP600125, a selective inhibitor of c-Jun N-terminal kinase, blocked hBD-2 induction by E. coli Nissle 1917 in Caco-2 cells. SB 202190, a specific p38 mitogen-activated protein kinase inhibitor, and PD 98059, a selective inhibitor of extracellular signal-regulated kinase 1/2, were ineffective. This report demonstrates that probiotic bacteria may stimulate the intestinal innate defense through the upregulation of inducible antimicrobial peptides such as hBD-2. The induction of hBD-2 may contribute to an enhanced mucosal barrier to the luminal bacteria.
Cited by
- Manipulation of feeding patterns in high fat diet fed rats improves microbiota composition dynamics, inflammation and gut-brain signaling
- The Front Line of Enteric Host Defense against Unwelcome Intrusion of Harmful Microorganisms: Mucins, Antimicrobial Peptides, and Microbiota
- Intestinal defensin secretion in infancy is associated with the emergence of sensitization and atopic dermatitis
- Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. [europepmc]
- Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. [europepmc]
- TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. [europepmc]
- Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). [europepmc]
- Probiotics-host communication: Modulation of signaling pathways in the intestine. [europepmc]
- Probiotics, enteric and diarrheal diseases, and global health. [europepmc]
- A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. [europepmc]
- Innate immune signaling in defense against intestinal microbes. [europepmc]
- Oral supplementation with Lactobacillus delbrueckii subsp. bulgaricus 8481 enhances systemic immunity in elderly subjects. [europepmc]
- Cationic host defence peptides: potential as antiviral therapeutics. [europepmc]
- Probiotic bacteria reduce salmonella typhimurium intestinal colonization by competing for iron. [europepmc]
- Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. [europepmc]
- Activation of Immune and Defense Responses in the Intestinal Mucosa by Outer Membrane Vesicles of Commensal and Probiotic Escherichia coli Strains. [europepmc]
- Can probiotics modulate human disease by impacting intestinal barrier function? [europepmc]
- Bacillus subtilis Improves Immunity and Disease Resistance in Rabbits. [europepmc]
- Lactobacillus reuteri I5007 Modulates Intestinal Host Defense Peptide Expression in the Model of IPEC-J2 Cells and Neonatal Piglets. [europepmc]
- Blueberry Supplementation Influences the Gut Microbiota, Inflammation, and Insulin Resistance in High-Fat-Diet-Fed Rats. [europepmc]
- The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. [europepmc]
- Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease. [europepmc]
- The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity. [europepmc]
- Interactions Between the Gut Microbiota and the Host Innate Immune Response Against Pathogens. [europepmc]
- The Immunomodulatory Properties of Extracellular Vesicles Derived from Probiotics: A Novel Approach for the Management of Gastrointestinal Diseases. [europepmc]
- Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome. [europepmc]
- Structural diversity, functional aspects and future therapeutic applications of human gut microbiome. [europepmc]
- Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis. [europepmc]
Related